07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Abzena, Alpha Cancer deal

Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will use its ThioBridge linker technology to attach an undisclosed cytotoxic drug to Alpha Cancer's recombinant human alpha fetoprotein...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Alpha Cancer, Bradmer deal

The companies signed a letter of intent to combine businesses through a reverse merger with the newco to be named Alpha Cancer Technologies Inc. The close is subject to Alpha Cancer completing a private placement...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

Bradmer, Epic Production Technologies International Inc. deal

The companies mutually terminated a letter of intent to combine businesses through a reverse merger. Bradmer said it intends to seek out new opportunities. The company said it expects its shares will resume trading on...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Bradmer, Epic Production Technologies International Inc. deal

The companies signed a letter of intent to combine businesses through a reverse merger with the new company named Epic Production Technologies International Inc. The close, which is expected in 1Q12, is subject to Epic...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Financial News

Bradmer completes private placement

Bradmer Pharmaceuticals Inc. (TSX:BMR), Toronto, Ontario   Business: Cancer   Date completed: 7/29/10   Type: Private placement   Raised: C$499,999 (US$488,849)   Shares: 5.3 million   Price: C$0.10   Shares after offering: 19.7 million  ...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Financial News

Bradmer completes private placement

Bradmer Pharmaceuticals Inc. (TSX:BMR), Toronto, Ontario   Business: Cancer   Date completed: 3/26/10   Type: Private placement   Raised: C$795,145 (US$778,447)   Shares: 8.4 million   Price: C$0.10   Shares after offering: 14.4 million  ...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) Tenascin C (TNC; TN); toll-like receptor 4 (TLR4) Studies in cell culture and in mice suggest that targeting TNC could help...
07:00 , Jul 6, 2009 |  BioCentury  |  Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
07:00 , May 18, 2009 |  BC Week In Review  |  Company News

Bradmer cancer news

The company reduced headcount by six (67%) to about three to conserve cash as it continues to evaluate strategic alternatives. In February, Bradmer said it would not have sufficient cash to complete the Phase III...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Neuradiab: Phase III delayed

Bradmer said slow enrollment due to slow site initiation in the ongoing Phase III GLASS-ART trial of Neuradiab has prompted the company to evaluate strategic alternatives after the delay meant it would no longer have...